Close Menu

NEW YORK (GenomeWeb) – MIODx has closed a $1.5 million seed round, the company announced today. The funding will be used to complete a clinical utility study for the firm's VerifyDx Prostate Cancer test and to begin commercialization.

The startup also announced that it has entered into a lease for 3,000 square feet of space at the San Jose BioCube, also home to Ariosa Diagnostics, Geneweave, and Genia.

The VerifyDx system is a multiplexed PCR-based oncology testing platform that examines DNA and RNA pathways implicated in metastatic cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).